Phosphodiesterase Type 5 (PDE-5) Inhibitor Utilization Among Women

    Basic Details
    Date Posted
    Thursday, October 11, 2018
    Medical Product
    phosphodiesterase type 5 (PDE5) inhibitor

    The goal of this query was to estimate phosphodiesterase type 5 (PDE5) inhibitor utilization among women in the Sentinel Distributed Database (SDD). Report 1 contains estimates of phosphodiesterase type 5 (PDE5) inhibitor use among reproductive-aged women. Report 2 contains estimates of PDE5 inhibitor use that occurred during a pregnancy ending in a live-born delivery or within 90 days prior to pregnancy start, among women. Data from January 1, 2001 to March 31, 2018 from 16 Data Partners contributing to the SDD were included in this report. This request was distributed to Data Partners on August 27, 2018. 

    Additional Details
    FDA Center
    Time Period
    January 1, 2001 - March 31, 2018
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    Females 15 to 50 years of age
    Data Sources
    Sentinel Distributed Database (SDD)